imaging of the 10-year-old patient was mostly comparable to those previously reported. Organabsorbed dose for the salivary glands was 98.0 Gy, heart wall 36.5 Gy, and liver 34.3 Gy, while tumor-absorbed dose ranged from 143.9 to 1,641.3 Gy in different sites. 
I]mIBG positron emission tomography/X-ray computed tomography (PET/CT) imaging with a GEometry ANd Tracking 4 (Geant4)-based Monte Carlo method for better treatment planning. Procedures: A Monte Carlo dosimetry method was developed using the Geant4 toolkit with voxelized anatomical geometry and source distribution as input. The presegmented hybrid computational human phantoms developed by the University of Florida and the National Cancer Institute (UF/NCI) were used as a surrogate to characterize the anatomy of a given patient. S values for I-131 were estimated by the phantoms coupled with Geant4 and compared with those estimated by OLINDA|EXM and MCNPX for the newborn model. To obtain patient-specific biodistribution of [ The organ-and tumor-absorbed doses of the clinical case were estimated with the Geant4 method using the modified UF/NCI 10-year-old phantom with tumors and the patient-specific residence time. Results: For the newborn model, the Geant4 S values were consistent with the MCNPX S values. The S value ratio of the Geant4 method to OLINDA|EXM ranged from 0.08 to 6.5 of all major organs. The [ Introduction N euroblastoma is a neuroendocrine tumor of children derived from neural crest in the sympathetic nervous system. Half of neuroblastoma cases are metastatic at diagnosis, with a long-term survival rate less than 40 % with intensive multimodality therapy including chemotherapy induction, surgery, radiotherapy, myeloablative treatment, and therapy for minimal residual disease [1] [2] [3] . Iodine-131-m-iodobenzylguanidine ([ 131 I]mIBG) was introduced as another approach to treat neuroblastoma with targeted radionuclide therapy (TRT). Since mIBG has a similar transport mechanism to norepinephrine, 90 % of neuroblastoma is mIBG avid [4, 5] . [ 131 I]MIBG TRT has become a standard treatment approach for recurrent or refractory cases of neuroblastoma with response rates of 20-37 % [2, 3, [6] [7] [8] .
Currently, [ 131 I]mIBG TRT treatment planning has been based on the maximum tolerable dose per patient's body weight, and internal dosimetry from the treatment has been approximated with planar imaging and OLINDA|EXM. While OLINDA|EXM is a useful tool for internal dosimetry, several studies [9] [10] [11] [12] have reported that the stylized phantoms [13] built into OLINDA|EXM (version 1.1) and realistic voxel phantoms yields a dose discrepancy, which may be pertinent to address for therapy planning. Recent efforts have been made in updating radiation dosimetry in OLINDA by considering realistic voxelized reference human phantoms. Since [14] [15] [16] has been shown to be helpful to estimate radiation dose.
In this study, a GEometry ANd Tracking 4 (Geant4) [17, 18] Monte Carlo method was investigated for use with [ 124 I]mIBG pretherapy PET/CT imaging to estimate radiation dose close to patient-specific dosimetry. Dose estimates from the Geant4 dosimetry method, OLINDA|EXM [19] , and the data published by Wayson et al. [20] 
Materials and Methods

Computational Human Phantoms
Nonuniform rational B-spline (NURBS) hybrid computational phantoms developed by the University of Florida (UF) and the National Cancer Institute (NCI) [21, 22] were used to describe human anatomy in the Monte Carlo simulation. The UF/NCI phantoms define 126 anatomical organ and tissue models including 38 skeletal sites. The UF/NCI newborn and 10-year-old female phantoms were used to define anatomical geometry realistic to the human in the simulation because organs and tissues are already segmented in the UF/NCI phantoms, which will substantially eliminate the time for segmenting the CT images. Tissue composition and density of the UF/NCI phantoms were defined according to Lee et al. [21] . The UF/NCI phantoms were generated with an isotropic voxel resolution of 1.0 mm
where E is the energy per radiation (MeV), y i is the number of radiations with energy E i emitted per nuclear transition, ϕ i (r T ←r S ) is the fraction of energy emitted that is absorbed in the target, k is the constant (Gy-kg/MBq-s-MeV), and m rT is the mass of target region. For all nonskeletal source and target organs, S values of a given radionuclide were calculated using Eq. 1. For the skeletal target tissues, dose enhancement from photons to S value S photon (r T ←r S ) was estimated using the skeletal photon dose response function (DRF) precalculated for the UF/NCI phantoms [24] as follows:
where w j (r T ) is the mass fraction of the target tissue r T in bone site j, D(r T )/F(E i ) is the skeletal photon DRF for the target tissue r T at photon energy E i , F(j←r S ;E i ) is the photon flux emitted from the source organ r S incident on the spongiosa or medullary cavity of the bone site j for photon energy E i . The mass fraction of the skeletal tissues reported for the UF/NCI newborn phantom [25] was used for S value to skeletal target tissue. Since photons or gamma rays emitted from any organ are the predominant particles depositing dose in the skeletal tissues, S(r T ←r S )≈S photon (r T ←r S ) was assumed for all nonskeletal source organs to skeletal target tissues.
For skeletal source tissues, the dose enhancement in the S value from electrons S electron (r T ←r S ) was computed as
where N(E i ) is the number of electrons emitting from the skeletal source tissue and Φ(j←r S ;E i ) is the skeletal-averaged electron specific absorbed fraction (g −1 ). Φ(j←r S ;E i ) precalculated for the UF/NCI newborn phantom [26] was used to estimate the S value. Since dose contribution from electrons and photons was considered for all skeletal source tissues to skeletal target tissues, S(r T ←r S )=S photon (r T ←r S )+S electron (r T ←r S ) was assumed. Due to unavailable skeletal-averaged electron specific absorbed fraction for the 10-year-old phantom and bone marrow mass, the skeletal dosimetry in the UF/NCI 10-year-old phantom was approximated by considering dose enhancement from only photons. The mass of active marrow of the UF/NCI 10-year-old phantom was approximated by the mass proportion reported in Table 1 of Xie et al. 2013 [27] .
Monte Carlo Particle Transport
An internal dosimetry tool was developed using the Geant4 Monte Carlo particle transport toolkit (version 4.9.6.p02). The dosimetry tool allows flexible definition of geometry and source distribution. G4VNestedParameterization was implemented to enable voxelized geometry definition in the simulation geometry with efficient particle transport. The user-defined primary source distribution was implemented in the G4UserPrimaryGenerator to randomly sample primary source position based on a given probability distribution. The primary source was uniformly distributed in a given organ with isotropic angular momentum. Geant4 modular physics lists including G4RadioActiveDecayPhysics, G4DecayPhysics, and G4EmStandardPhysics_option4 were enabled to simulate the radioactive decay processes and physics processes in the lowenergy regime. The radioactive decay products were sampled based on the Evaluated Nuclear Structure Data File (ENSDF) data library [28] . A threebody decay algorithm was used to sample the β-decay spectrum [29] . A range cutoff of 0.1 mm was set for all particles. In order to compute S values appropriately, three derived classes of G4VPrimitiveScorer via G4MultiFunctionalDetector were constructed to score the following hit information in the voxelized geometry: the total energy deposit (MeV), the photon flux (cm
) per energy bin, and the energy histogram of electrons in the source tissue.
Ten million and twenty million histories in each source organ were simulated for the newborn and the 10-year-old phantoms, respectively. All simulations were performed on a Relion 2800GT server (Penguin Computing, Fremont, CA) with sixteen 2.7-GHz Intel Xeon E5-2680 cores and 256 GB of available memory. Monte Carlo simulations were performed in 10 batches of 10-million or 20-million histories. Each batch was initialized with a different random number seed. The coefficient of variation (CV) was expressed as a percentage of the mean of the ten S values measured for each source organ.
For benchmarking purposes, the Geant4 S values computed for the UF/NCI newborn phantom were cross-checked with those computed with Monte Carlo N-Particle eXtended (MCNPX) in Wayson et al. [20] . In addition, Geant4 S values were compared with the mass-adjusted S values from OLINDA|EXM (version 1.1) for the newborn and the 10-year-old models. Due to the different skeletal dosimetry approach used in this study, the mass of red marrow and osteogenic cells was not modified in OLINDA for the Geant4 and OLINDA comparison. To estimate patient-specific dosimetry, the UF/NCI 10-year-old female phantom was used for its body size and anatomy, similar to those of the clinical case. Source organs identified in the [ 124 I]mIBG PET images of the clinical case include urinary bladder, brain, liver, lungs, salivary glands, spleen, and thyroid. In addition, 12 lesions were identified in the patient and were contoured using PMOD. All lesions were bone metastases, and CT images could not determine a meaningful tumor volume. Thus, tumor volume was approximated by the metabolic tumor volume [31] using the [ 124 I]mIBG PET images. The metabolic tumor volume was defined as the volume of hypermetabolic tissue with a threshold of greater than 50 % of the maximum uptake in the entire tumor site. We used the threshold of 50 % of the maximum uptake following a phantom study in Ciernick et al. [32] . The metabolic tumor volumes were then carefully placed in the UF/NCI 10-year-old phantom as close as possible to the tumor location in the clinical case. The modified UF/NCI 10-year-old phantom was the input geometry to the Geant4 method with [ 
Results
For one source organ, the average time of the I-131 Monte Carlo simulations was 5.2 h (10-million events) and 19.5 h (20-million events) for UF/NCI newborn phantom and UF/ NCI 10-year-old phantom, respectively.
Benchmark of S Values Between MCNPX and Geant4
The S values of the Geant4 dosimetry method were benchmarked with those simulated with the same UF/NCI newborn phantom in the study of Wayson et al. [20] using MCNPX. For the adrenal source in the UF/NCI newborn phantom, Fig. 1 shows that the Geant4 S values consistently agree with the MCNPX S values. The S value ratio of Geant4 to MCNPX was close to unity ranging from 0.90 to 1.1. Supplemental Table 1 shows consistent agreement in the newborn S values between Geant4 and MCNPX with a ratio ranging between 0.23 and 1.13 for nonskeletal organs while some discrepancies were observed in the hollow organs and skeletal tissues.
S value Comparison Between OLINDA|EXM and Geant4
The S value differences between the Geant4 dosimetry method and OLINDA were examined. For the adrenal source in the newborn model, the mean S value (±standard deviation, mGy/MBq-s) computed by Geant4 and OLINDA is compared in Fig. 2 . The Geant4 method suggests that the self-irradiation dose was 97.3 % (OLINDA 98.1 %) of total organ dose while the cross-irradiation dose to other organs ranged from 0.09 to 0.46 % of total organ dose (OLINDA 0.06 to 0.35 %). The S value ratio of Geant4 to OLINDA ranges between 0.59 (heart wall target) and 2.4 (stomach wall target). For all major organs in the newborn and the 10-year-old models, Supplemental Tables 2-4 show that the self-irradiation S values were consistent between Geant4 and Fig. 1 The comparison of the I-131 S value (mGy/MBq-s)±standard deviation for the newborn model between the Geant4 method (left red bar) and the MCNPX method (right blue bar) is shown. For the adrenal source, the S value ratio between Geant4 and MCNPX is shown above the bar for all target organs. The self-irradiation S value for the adrenal source was not included in the plot due to substantial difference in order of magnitude comparing to the cross-irradiation S values. UB: urinary bladder, LLI: lower large intestine, ULI: upper large intestine, SI: small intestine, St: stomach. Fig. 2 The comparison of the I-131 S value (mGy/MBq-s)±standard deviation for the newborn model between the Geant4 method (left red bar) and OLINDA|EXM (right gray bar) is shown. For the adrenal source, the S value ratio between Geant4 and OLINDA|EXM is shown above the bar for all target organs. The self-irradiation S value for the adrenal source was not included in the plot due to substantial difference in order of magnitude comparing to the cross-irradiation S values.
OLINDA while differences were found for small organs and between organs that are anatomically distant, which give rise to larger S value CV. Figure 4 shows a visual comparison of the anatomy modeled in the Geant4 method and OLINDA with the clinical CT images. Supplemental Figs. 1 and 2 show that the large difference in the organ contour and positions between the UF/NCI and the stylized phantoms resulted in nonnegligible S value discrepancy. ]mIBG TACs in all major organs except the heart, the thyroid, and the liver were found to be within the range of those estimated in the previous studies in Table 1 . Figure 6 identifies Tables 1 and 2 
Discussion
A dosimetry approach of [
131 I]mIBG TRT was introduced by using patient-specific residence time quantified from pretherapy [
124 I]mIBG PET/CT imaging and realistic anatomy in the Monte Carlo simulations. Overall, the S values from the Geant4 method were similar to the OLINDA S values for self-irradiation while some discrepancy was observed for cross-irradiation, especially among distant and smaller organs. Consistent agreement in S values between Geant4 and MCNPX confirms the integrity of the Geant4 method using the same UF/NCI newborn phantoms. This study also shows that this dosimetry method is feasible to estimate absorbed dose to normal organs and tumors close to those specific to a given patient. In addition, the Geant4 method has full freedom in modeling the clinical environment realistic to a patient, such as lesion location and detailed particle information.
There are several factors to consider when comparing the dosimetry result between the Geant4 method and OLINDA|EXM or MCNPX. The S values from the Geant4 dosimetry method were estimated with the UF/NCI phantoms, which is anatomically different from Cristy and Eckerman stylized phantoms [13] used in OLINDA|EXM. The S value discrepancy between Geant4 and OLINDA in this study is mainly due to the difference in human anatomy and contour defined in the Monte Carlo particle transport. The distance and contour in the stylized phantoms are quite different from those in the UF/NCI phantoms, which represent more realistic human anatomy. Supplementary  Fig. 1 shows that the large S value difference between the Geant4 method and OLINDA to the thymus source organ could likely due to very different organ position and contour between the UF/NCI phantom and the stylized phantom. It also shows that the UF/NCI phantom provided human anatomy more realistic to the clinical CT images, which could improve the accuracy of the dose estimate. Supplementary Fig. 2 suggests that difference in inter-organ distance modeled in the UF/NCI and the stylized phantoms can contribute to the S value difference between the Geant4 method and OLINDA. For example, the stylized newborn phantom modeled the stomach by an ellipsoid shape with a gap from the kidney approximately 17 mm larger than that ]mIBG PET/CT images, the absorbed dose estimated by the dosimetry method in this study, percent of the total absorbed dose from the cross-irradiation, and percent of the total absorbed dose from the self-irradiation are listed for all lesions identified in the clinical case in this study. in the UF/NCI phantom with more realistic organ contour. Different particle transport methods could contribute to the S value difference between OLINDA and Geant4. OLINDA used the ALGAMP Monte Carlo code [33] by tracking electrons and photons separately to obtain monoenergetic specific absorbed fractions while radioactive decay products were directly simulated in the Geant4 method. OLINDA used a skeletal dosimetry model that assumed that the skeletal DRF for all the bone sites can be simply represented by those of parietal bone and lumbar vertebra [13] . On the contrary, the UF/NCI phantoms were developed with a detailed skeletal dosimetry model that computed skeletal DRF 40 bone sites based on micro-CT images of the bone sites. For the wall or content of hollow organs, the S value difference between Geant4 and OLINDA or MCNPX may be attributed to the analytical definition of S values from content to wall [34] in OLINDA and the variance reduction techniques implemented in the MCNPX method. Other factors such as tissue composition, density, and Monte Carlo transport physics of photons and electrons for the energy range of interest can contribute the S value difference between Geant4 and other methods. The pretherapy [ 124 I]mIBG PET/CT imaging of the 10-year-old patient serves as a good example to evaluate the efficacy of the Geant4 dosimetry method for more realistic dosimetry planning in a clinical setting. The UF/NCI hybrid computation phantoms include a family of human phantoms with various age and body size [35] ; thus, one can select a UF/NCI phantom that best resembles the anatomy of a given patient as the input to the Geant4 dosimetry tool. This approach eliminates the time spent to segment or contour organs of interest on the CT images for the geometry input to the Geant4 method. The process of outlining organs or volume of interest may be time-prohibitive and error-prone especially with low-dose CT images for PET attenuation correction, not to mention the uncertainty introduced in estimating the material density from the CT Hounsfield units. Furthermore, one can modify the UF/NCI phantoms by incorporating realistic tumor volumes at any given location. Any radionuclide can be simulated for a given source distribution such as nonuniform distribution. Thus, the dosimetry may be estimated with this flexible Geant4 method and not limited by capability of existing dosimetry software. For example, [
124 I]mIBG PET images of the patient indicated some mIBG uptake in the salivary glands. S values of salivary glands were not available in OLINDA, which may neglect considerable absorbed dose to salivary glands (Table 3 (Table 1) compared to those reported in the past studies. The small study sample size and the different thyroid blocking methods could contribute to the deviation in residence time of the heart and the thyroid estimated in this study. In this study, the patient-specific dosimetry was referred to the dose estimated with the Geant4 method considering a realistic human anatomy and patientspecific residence time quantified from the [ ]mIBG TRT by considering toxicity to dose-limiting organs such as the bone marrow and liver. For this clinical case, self-irradiation mainly contributed to the absorbed dose of tumors that were distant from other source organs. While tumor self-irradiation dose may be a good assumption, this study estimated some cross-irradiation from the lung source contributing to lesions no. 9 and no. 10 located close to the lungs. Although the percent cross-irradiation of these lesions is less than 5 %, the residence time and the location of tumor to other source organs could affect the absorbed dose to tumors in ways that might not be addressed simply by the self-irradiating sphere model. Matthay et al. [36] reported similar tumor-absorbed dose ranging from 31.2 to 3,050 Gy from a cohort who received a median [ 131 I]mIBG activity of 15 mCi/kg using conjugate planar imaging and OLINDA|EXM. Furthermore, the patientspecific TACs and 3D dose distribution of organs and tumors may be helpful to further optimize the treatment planning.
There are limitations to consider in this study. The assumptions made in calculating skeletal dosimetry of the UF/NCI 10-year-old phantom may introduce uncertainty in the S value from the skeletal source or target tissue, which was included in the S value of total body as a source or target organ. Since the [ 131 I]mIBG residence time of the remainder body was high among other source organs in this study, the uncertainty from the skeletal dosimetry may contribute error in the final absorbed dose. The accuracy of total [
131 I]mIBG uptake quantified by the PET images may be affected by the contoured VOIs and partial volume effect in the reconstructed PET images. Although the modified UF/ NCI phantoms are helpful in defining realistic geometry in the Monte Carlo simulations for much improved dose estimate, the absorbed dose was not truly patient-specific because the UF/NCI phantoms and the patient anatomy are not identical. Comparison of the dose estimate between the UF/NCI phantoms and the clinical CT images will be investigated in the future studies.
Conclusion
This study demonstrated the feasibility of estimating patientspecific dosimetry of 
